Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tepotinib + osimertinib
- Development stage
- Phase 2
- Lead developer
- EMD Serono
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Tepotinib + osimertinib is a combination therapy used to treat EGFR-mutant non-small cell lung cancer (NSCLC) with MET amplification as a mechanism of acquired resistance to first-line osimertinib treatment. This oral targeted therapy combines tepotinib, a highly selective MET tyrosine kinase inhibitor, with osimertinib, an EGFR tyrosine kinase inhibitor. MET amplification occurs in up to 30% of patients with NSCLC who progress on first-line osimertinib. The combination aims to overcome MET amplification-driven resistance by simultaneously targeting both pathways.
- Other names
- osimertinib plus tepotinibtepotinib plus osimertinib
02
Targets
EGFR (Epidermal growth factor receptor)MET (Mesenchymal-epithelial transition factor receptor)
Beyond the preview
Go deeper on tepotinib + osimertinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tepotinib + osimertinib.